{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:40Z","timestamp":1787021260071,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurol Neuroimmunol Neuroinflamm"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1212\/nxi.0000000000000070","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T22:24:02Z","timestamp":1423779842000},"update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":58,"title":["Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens"],"prefix":"10.1212","volume":"2","author":[{"given":"Amit","family":"Bar-Or","sequence":"first","affiliation":[{"name":"From the Montreal Neurological Institute (A.B.-O.), McGill University, Montreal, Quebec, Canada; University of M\u00fcnster (H.W.), M\u00fcnster, Germany; Sanofi (B.M.), Bridgewater, NJ; Genzyme, a Sanofi company (M.B., P.T., F.M.-V.), Chilly-Mazarin, France; and Fishawack Communications, Inc. (M.C.), Horsham, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[{"name":"From the Montreal Neurological Institute (A.B.-O.), McGill University, Montreal, Quebec, Canada; University of M\u00fcnster (H.W.), M\u00fcnster, Germany; Sanofi (B.M.), Bridgewater, NJ; Genzyme, a Sanofi company (M.B., P.T., F.M.-V.), Chilly-Mazarin, France; and Fishawack Communications, Inc. (M.C.), Horsham, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Miller","sequence":"additional","affiliation":[{"name":"From the Montreal Neurological Institute (A.B.-O.), McGill University, Montreal, Quebec, Canada; University of M\u00fcnster (H.W.), M\u00fcnster, Germany; Sanofi (B.M.), Bridgewater, NJ; Genzyme, a Sanofi company (M.B., P.T., F.M.-V.), Chilly-Mazarin, France; and Fishawack Communications, Inc. (M.C.), Horsham, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Benamor","sequence":"additional","affiliation":[{"name":"From the Montreal Neurological Institute (A.B.-O.), McGill University, Montreal, Quebec, Canada; University of M\u00fcnster (H.W.), M\u00fcnster, Germany; Sanofi (B.M.), Bridgewater, NJ; Genzyme, a Sanofi company (M.B., P.T., F.M.-V.), Chilly-Mazarin, France; and Fishawack Communications, Inc. (M.C.), Horsham, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Truffinet","sequence":"additional","affiliation":[{"name":"From the Montreal Neurological Institute (A.B.-O.), McGill University, Montreal, Quebec, Canada; University of M\u00fcnster (H.W.), M\u00fcnster, Germany; Sanofi (B.M.), Bridgewater, NJ; Genzyme, a Sanofi company (M.B., P.T., F.M.-V.), Chilly-Mazarin, France; and Fishawack Communications, Inc. (M.C.), Horsham, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Church","sequence":"additional","affiliation":[{"name":"From the Montreal Neurological Institute (A.B.-O.), McGill University, Montreal, Quebec, Canada; University of M\u00fcnster (H.W.), M\u00fcnster, Germany; Sanofi (B.M.), Bridgewater, NJ; Genzyme, a Sanofi company (M.B., P.T., F.M.-V.), Chilly-Mazarin, France; and Fishawack Communications, Inc. (M.C.), Horsham, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Menguy-Vacheron","sequence":"additional","affiliation":[{"name":"From the Montreal Neurological Institute (A.B.-O.), McGill University, Montreal, Quebec, Canada; University of M\u00fcnster (H.W.), M\u00fcnster, Germany; Sanofi (B.M.), Bridgewater, NJ; Genzyme, a Sanofi company (M.B., P.T., F.M.-V.), Chilly-Mazarin, France; and Fishawack Communications, Inc. (M.C.), Horsham, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_8_2_2","volume-title":"AUBAGIO Prescribing Information","year":"2012","unstructured":"AUBAGIO Prescribing Information. Cambridge, MA: Genzyme Corporation, a Sanofi company; 2012."},{"key":"e_1_3_8_3_2","volume-title":"AUBAGIO Summary of Product Characteristics","year":"2013","unstructured":"AUBAGIO Summary of Product Characteristics. Paris, France: sanofi-aventis groupe; 2013."},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj3360299"},{"key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0022-3565(25)12093-4","article-title":"The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis","volume":"275","author":"Cherwinski HM","year":"1995","unstructured":"Cherwinski HM, Cohn RG, Cheung P, et al.. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043\u20131049.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.34.21682"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200027547"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01444.x"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.02.011"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.10.003"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0212-x"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.8"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31829e6fbf"},{"key":"e_1_3_8_14_2","volume-title":"Updated WHO Position Paper on Rabies Vaccines","author":"World Health Organization","unstructured":"World Health Organization. Updated WHO Position Paper on Rabies Vaccines. Available at: http:\/\/www.who.int\/immunization\/Rabies_slides_Aug_2010.pdf. Accessed November 24, 2014."},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.98"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011427908"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.25034"},{"key":"e_1_3_8_18_2","unstructured":"National Institutes of Health. The effects of Tysabri treatment on vaccination response and lymphocyte subsets in subjects with relapsing forms of multiple sclerosis. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00536120. Accessed November 25 2014."},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2008.00936.x"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/313610"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOCI.0000010429.36461.6b"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328354648e"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-007-9120-0"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328331a43b"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014656"},{"key":"e_1_3_8_26_2","first-page":"P544","article-title":"Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial","volume":"19","author":"Freedman M","year":"2013","unstructured":"Freedman M, Wolinsky JS, Comi G, et al.. Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Mult Scler J 2013;19(suppl 11):P544.","journal-title":"Mult Scler J"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.82.10_supplement.P2.194"},{"key":"e_1_3_8_28_2","first-page":"P1107","article-title":"Teriflunomide selectively suppresses antigen induced T-cell expansion in a TCR avidity dependent fashion","volume":"18","author":"Posevitz V","year":"2012","unstructured":"Posevitz V, Chudyka D, Schneider-Hohendorf T, Schwab N, Kurth F, Wiendl H. Teriflunomide selectively suppresses antigen induced T-cell expansion in a TCR avidity dependent fashion. Mult Scler J 2012;18:P1107.","journal-title":"Mult Scler J"},{"key":"e_1_3_8_29_2","first-page":"177","article-title":"An update of teriflunomide for treatment of multiple sclerosis","volume":"9","author":"Oh J","year":"2013","unstructured":"Oh J, O'Connor PW. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag 2013;9:177\u2013190.","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.7.938"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(98)00139-7"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf098"}],"container-title":["Neurology Neuroimmunology &amp; Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/NXI.0000000000000070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T19:56:36Z","timestamp":1747598196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000000070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1212\/NXI.0000000000000070"],"URL":"https:\/\/doi.org\/10.1212\/nxi.0000000000000070","relation":{},"ISSN":["2332-7812","2332-7812"],"issn-type":[{"value":"2332-7812","type":"print"},{"value":"2332-7812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]},"article-number":"e70"}}